Mixed Hepatocellular-cholangiocarcinoma Clinical Trials in Shanghai, Shanghai Municipality

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)